NAMSA and Fortuna Clinical have engaged in a strategic partnership to expand their support and expertise in the cardiovascular arena. Photo credit: www.cstoredecisions.com
NAMSA, a global medical research organization, and Fortuna Clinical, a global medical device clinical research organization, are pleased to announce their strategic relationship. As a result of the increase in demand of NAMSA’s clinical services driven by the development of the MRO Approach, NAMSA and Fortuna Clinical have engaged in a strategic partnership to expand their support and expertise in the cardiovascular arena.
“We are excited to join forces with Dr. Jan Skowronski and Fortuna Clinical so cardiovascular device manufacturers can have the benefit of expert regulatory, laboratory, clinical and medical expertise to cover all facets of patient safety and product efficacy benefits from a single source,” said John Gorski, president and CEO of NAMSA. “Ultimately, this helps accelerate our clients’ product development effort from bench to bedside.”
“Cardiovascular device studies are our passion,” said Jan Skowronski, MD, MBA and CEO of Fortuna Clinical. “In the past I have served as an investigator in multiple device trials and we use our experience and expertise in strengthening NAMSA’s position in cardiovascular clinical trials. We consider Fortuna Clinical to be a CRO ‘with a twist,’ as we believe that the best outcome of a clinical study can only be achieved by close collaboration with the investigators, including assistance with case selection and strong clinical support. In all aspects of medicine, but especially in a setting of a clinical trial, each subject should be treated like our own family member.”
Fortuna Clinical provides NAMSA expertise and access to high growth areas for cardiovascular clinical trial implementation, like Eastern Europe, and will allow for NAMSA to further expand its presence in Western and Central Europe, Asia Pacific and North America. The strategy to join forces with Fortuna continues to reinforce and expand the benefits of NAMSA’s MRO offering, reducing the time to market and the cost to launch new medical device products.
“We are thrilled about our partnership with NAMSA, and we are confident that our relationship will position NAMSA as the future market leader in worldwide cardiovascular clinical trials,” said Peter Kopczynski, MBA, COO of Fortuna Clinical.
With this partnership, NAMSA will continue to provide world-class industry leading strategies and services for market approval and market adoption of medical devices for medical device manufacturers. Through its global MRO Approach, thousands of clients worldwide benefit from NAMSA’s combination of regulatory and quality consulting, laboratory testing and clinical services to solve problems, build value and reduce risk.
NAMSA
www.namsa.com
Fortuna Clinical
www.fortunaclinical.com
